Browsing Molecular Pathology by author "Huang, Paul"

Now showing items 21-40 of 66

    • Exploiting vulnerabilities in cancer signalling networks to combat targeted therapy resistance. 

      Harrison, PT; Huang, PH (PORTLAND PRESS LTD, 2018-10-26)
      Drug resistance remains one of the greatest challenges facing precision oncology today. Despite the vast array of resistance mechanisms that cancer cells employ to subvert the effects of targeted therapy, a deep understanding ...

    • Fibroblast Growth Factor Receptor (FGFR) Signaling in GIST and Soft Tissue Sarcomas. 

      Napolitano, A; Ostler, AE; Jones, RL; Huang, PH (MDPI, 2021-06-17)
      Sarcomas are a heterogeneous group of rare malignancies originating from mesenchymal tissues with limited therapeutic options. Recently, alterations in components of the fibroblast growth factor receptor (FGFR) signaling ...

    • Fibroblastic Reticular Cells Control Conduit Matrix Deposition during Lymph Node Expansion. 

      Martinez, VG; Pankova, V; Krasny, L; Singh, T; Makris, S; et al. (CELL PRESS, 2019-11-26)
      Lymph nodes (LNs) act as filters, constantly sampling peripheral cues. This is facilitated by the conduit network, a tubular structure of aligned extracellular matrix (ECM) fibrils ensheathed by fibroblastic reticular cells ...

    • Functional genomic analysis of epithelioid sarcoma reveals distinct proximal and distal subtype biology. 

      Rasmussen, SV; Jin, JX; Bickford, LR; Woods, AD; Sahm, F; et al. (JOHN WILEY & SONS LTD, 2022-07-01)
      BACKGROUND: Metastatic epithelioid sarcoma (EPS) remains a largely unmet clinical need in children, adolescents and young adults despite the advent of EZH2 inhibitor tazemetostat. METHODS: In order to realise consistently ...

    • Future Directions in the Treatment of Osteosarcoma. 

      Smrke, A; Anderson, PM; Gulia, A; Gennatas, S; Huang, PH; et al. (MDPI, 2021-01-15)
      Osteosarcoma is the most common primary bone sarcoma and is often diagnosed in the 2nd-3rd decades of life. Response to the aggressive and highly toxic neoadjuvant methotrexate-doxorubicin-cisplatin (MAP) chemotherapy ...

    • Is the IDH Mutation a Good Target for Chondrosarcoma Treatment? 

      Cojocaru, E; Wilding, C; Engelman, B; Huang, P; Jones, RL (Springer Science and Business Media LLC, 2020-03-01)
      <jats:title>Abstract</jats:title><jats:p>Chondrosarcomas are rare cancers of bone that arise from the malignant transformation of cells of chondrocytic lineage. They are known to be resistant to systemic cytotoxic chemotherapy ...

    • Molecular profiling in desmoplastic small round cell tumours. 

      Tam, YB; Jones, RL; Huang, PH (PERGAMON-ELSEVIER SCIENCE LTD, 2023-04-01)
      Desmoplastic small round cell tumour (DSRCT) is an ultra-rare soft tissue sarcoma that is characterised by aggressive disease and dismal patient outcomes. Despite multi-modal therapy, prognosis remains poor and there are ...

    • Molecular subtypes of leiomyosarcoma: Moving toward a consensus 

      Burns, J; Jones, RL; Huang, PH (WILEY, 2022-12-01)

    • Next-generation sequencing for the management of sarcomas with no known driver mutations. 

      Vyse, S; Thway, K; Huang, PH; Jones, RL (LIPPINCOTT WILLIAMS & WILKINS, 2021-07-01)
      PURPOSE OF REVIEW: Next-generation sequencing (NGS) has enabled fast, high-throughput nucleotide sequencing and has begun to be implemented into clinical practice for genomic-guided precision medicine in various cancer ...

    • Novel therapeutic approaches in chondrosarcoma. 

      Polychronidou, G; Karavasilis, V; Pollack, SM; Huang, PH; Lee, A; et al. (FUTURE MEDICINE LTD, 2017-03-01)
      Chondrosarcoma is a malignant tumor of bones, characterized by the production of cartilage matrix. Due to lack of effective treatment for advanced disease, the clinical management of chondrosarcomas is exceptionally ...

    • Olaratumab in soft tissue sarcoma - Current status and future perspectives. 

      Antoniou, G; Lee, ATJ; Huang, PH; Jones, RL (ELSEVIER SCI LTD, 2018-03-01)
      Recent randomised phase II trial data have indicated that the addition of olaratumab, a novel monoclonal antibody against platelet-derived growth factor receptor alpha (PDGFRα), to doxorubicin confers an unprecedented ...

    • Optimal Clinical Management and the Molecular Biology of Angiosarcomas. 

      Chen, TW-W; Burns, J; Jones, RL; Huang, PH (MDPI, 2020-11-10)
      Angiosarcomas comprise less than 3% of all soft tissue sarcomas but have a poor prognosis. Most angiosarcomas occur without obvious risk factors but secondary angiosarcoma could arise after radiotherapy or chronic lymphedema. ...

    • Pazopanib in advanced soft tissue sarcomas. 

      Lee, ATJ; Jones, RL; Huang, PH (NATURE PUBLISHING GROUP, 2019-05-17)
      Pazopanib is the first and only tyrosine kinase inhibitor currently approved for the treatment of multiple histological subtypes of soft tissue sarcoma (STS). Initially developed as a small molecule inhibitor of vascular ...

    • Pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma. 

      Chamberlain, FE; Wilding, C; Jones, RL; Huang, P (TAYLOR & FRANCIS LTD, 2019-07-03)
      Introduction: Liposarcomas (LPS) are a heterogeneous group of adipocytic soft tissue sarcomas with limited treatment options in the advanced/metastatic setting. Pazopanib is a multi-target tyrosine kinase inhibitor (TKI) ...

    • Pharmacotherapy for liposarcoma: current and emerging synthetic treatments. 

      Chamberlain, F; Benson, C; Thway, K; Huang, P; Jones, RL; et al. (TAYLOR & FRANCIS LTD, 2021-04-21)
      Liposarcomas are rare tumors arising from adipocytic tissue and accounting for approximately 15-20% of all soft tissue sarcomas. Liposarcoma can be further classified into histopathological subtypes with variable ...

    • Phase III Soft Tissue Sarcoma Trials: Success or Failure? 

      Lee, ATJ; Pollack, SM; Huang, P; Jones, RL (SPRINGER, 2017-03-01)
      Two recently reported phase III randomised control trials (RCTs) have resulted in the registration of two new systemic therapies for advanced soft tissue sarcoma. Both of these trials' designs were informed by phase II ...

    • Predictive and prognostic transcriptomic biomarkers in soft tissue sarcomas. 

      Merry, E; Thway, K; Jones, RL; Huang, PH (NATURE PORTFOLIO, 2021-03-05)
      Soft tissue sarcomas (STS) are rare and heterogeneous tumours comprising over 80 different histological subtypes. Treatment options remain limited in advanced STS with high rates of recurrence following resection of localised ...

    • Primary Cilia Mediate Diverse Kinase Inhibitor Resistance Mechanisms in Cancer. 

      Jenks, AD; Vyse, S; Wong, JP; Kostaras, E; Keller, D; et al. (CELL PRESS, 2018-06-05)
      Primary cilia are microtubule-based organelles that detect mechanical and chemical stimuli. Although cilia house a number of oncogenic molecules (including Smoothened, KRAS, EGFR, and PDGFR), their precise role in cancer ...

    • Proteomic and Metabolomic Profiling in Soft Tissue Sarcomas. 

      Chadha, M; Huang, PH (SPRINGER, 2022-02-16)
      Advances in proteomic and metabolomic technologies have accelerated our understanding of multiple aspects of cancer biology across distinct tumour types. Here we review the current state-of-the-art in the use of proteomics ...

    • Proteomic profiling of soft tissue sarcomas with SWATH mass spectrometry. 

      Milighetti, M; Krasny, L; Lee, ATJ; Morani, G; Szecsei, C; et al. (ELSEVIER, 2021-06-15)
      Soft tissue sarcomas (STS) are a group of rare and heterogeneous cancers. While large-scale genomic and epigenomic profiling of STS have been undertaken, proteomic analysis has thus far been limited. Here we utilise ...